抗血小板治疗的出血风险控制.pptVIP

  • 8
  • 0
  • 约2.78万字
  • 约 109页
  • 2016-01-21 发布于浙江
  • 举报
Lowering APT dose? 50mg vs 75mg clopidogrel 50mg vs 75mg clopidogrel Ticagrelor 60mg bid VS 90mg bid PEGASUS Study Conclusion for lowering doses Lower doses may decrease bleeding Need more data to support the efficacy and safety Figure 1 Study End Points. Shown are Kaplan–Meier event rates at 2 years in the two study groups for the primary efficacy end point (a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) (Panel A) and the key secondary efficacy end point (a composite of death fr

文档评论(0)

1亿VIP精品文档

相关文档